<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658121</url>
  </required_header>
  <id_info>
    <org_study_id>CoVPN 5002</org_study_id>
    <nct_id>NCT04658121</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2/COVID-19 PREVALENCE STUDY</brief_title>
  <official_title>SARS-CoV-2 PREVALENCE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COVID-19 Prevention Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>COVID-19 Prevention Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 Prevention Network (CoVPN) is doing a study to estimate the number of people who&#xD;
      have or have had the SARS-CoV-2 virus in different communities in the United States. This&#xD;
      study is being done to help determine the best places to perform future research studies that&#xD;
      will test new drugs for treatment or prevention of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      Cross-sectional surveys of (1) nursing home and outpatient healthcare facilities, and (2) the&#xD;
      general population in each selected research site community through time-location sampling&#xD;
&#xD;
      Population:&#xD;
&#xD;
        1. Adults residing in nursing homes or attending outpatient healthcare facilities in&#xD;
           neighborhoods of selected research sites&#xD;
&#xD;
        2. Adults and children (&gt; 2 months of age) in neighborhoods of selected research sites&#xD;
&#xD;
      Study Size:&#xD;
&#xD;
      For each research site, 3,920 individuals will be enrolled from:&#xD;
&#xD;
        1. nursing homes/assisted living facilities (n = 500) and outpatient healthcare facilities&#xD;
           (n = 500), and&#xD;
&#xD;
        2. community surveys distributed across four age strata (0-17, 18-39, 40-59, 60+ years) (n&#xD;
           = 730 per stratum or 2920)&#xD;
&#xD;
      Total sample size = 3,920 x approximately 20-25 clinical research sites&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      Approximately one (1) year for overall project. Two (2) months for protocol development and&#xD;
      institutional review board (IRB) approval, followed by:&#xD;
&#xD;
        1. Facility-based surveys: 9 months (2 months for site preparation and initiation, 1 month&#xD;
           for enrollment/sample collection, 4 months for shipping and laboratory testing, 2 months&#xD;
           for close-out), concurrent with&#xD;
&#xD;
        2. Time-location sampling (TLS) surveys: 12 months (2 months for site preparation and&#xD;
           initiation, 2 months for enrollment/sample collection, 6 months for shipping and&#xD;
           laboratory testing, 2 months for close-out)&#xD;
&#xD;
      Study Location:&#xD;
&#xD;
      Catchment areas surrounding US-based Clinical Research Sites (CRSs) of the: HIV Prevention&#xD;
      Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), Infectious Diseases Clinical&#xD;
      Research Consortium (IDCRC), International Maternal Pediatric Adolescent AIDS Clinical Trials&#xD;
      Group (IMPAACT), and the AIDS Clinical Trials Group (ACTG); to be specified in the Site&#xD;
      Announcement Memo&#xD;
&#xD;
      Study Methods:&#xD;
&#xD;
      Blood collection for SARS-CoV-2 antibody testing and characterization of the serologic&#xD;
      response to SARS-CoV-2 infection; nasal mid-turbinate swab collection for SARS-CoV-2 RNA&#xD;
      testing; collection of saliva and/or oral fluid and dried blood spot samples (DBS) in a&#xD;
      subset of participants to evaluate the performance of diagnostic SARS-CoV-2 assays using&#xD;
      these matrices; administration of tablet-based survey. Medical records abstraction for&#xD;
      healthcare facility participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate seroprevalence of SARS-CoV-2</measure>
    <time_frame>Baseline</time_frame>
    <description>To estimate seroprevalence of SARS-CoV-2 among those without past or current symptoms consistent with COVID-19. Those with no prior positive SARS-CoV-2 testing, but who report close contact with confirmed or presumed cases. Those with history of co-morbid medical conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess correlation between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate potential size of populations for referral to COVID-19 prevention and treatment studies</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess knowledge, attitudes, and behavior about SARS-CoV-2 and COVID-19 through a study questionnaire</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare performance characteristics of PCR-based and serologic SARS-CoV-2 tests using saliva and/or oral fluid and DBS samples</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3920</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Nursing Homes</arm_group_label>
    <description>Adults residing in nursing homes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthcare Facilities</arm_group_label>
    <description>Adults attending outpatient healthcare in neighborhoods of selected research sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Communities</arm_group_label>
    <description>Adults and children (&gt;2 months of age) in neighborhoods of selected research sites.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, nasal swab, and saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Adults residing in nursing homes or attending outpatient healthcare facilities in&#xD;
             neighborhoods of selected research sites.&#xD;
&#xD;
          -  Adults and children (&gt;2 month of age) in neighborhoods of selected research sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults residing in nursing homes/assisted living facilities or attending outpatient&#xD;
             healthcare facilities&#xD;
&#xD;
               -  At least 18 years of age&#xD;
&#xD;
               -  Willing and able to provide informed consent or consent has been provided by&#xD;
                  legal representative (for those with mental incapacity)&#xD;
&#xD;
               -  Recruited from a selected facility&#xD;
&#xD;
          -  Adults and children from select neighborhoods of research site communities&#xD;
&#xD;
               -  Adults and children &gt; 2 months of age&#xD;
&#xD;
               -  For individuals &lt; 18 years old, a guardian must be present&#xD;
&#xD;
               -  Willing and able to provide consent (or assent for individuals &lt; 18 years,&#xD;
                  parent/guardian will provide consent)&#xD;
&#xD;
               -  Resident of the CRS catchment area or recruited from a selected venue&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current enrollment in any interventional COVID-19 clinical trial, including&#xD;
             studies involving prophylactic, therapeutic or immune modulating agents.&#xD;
&#xD;
          -  Previous enrollment in this study, either from the same or another CRS community.&#xD;
&#xD;
          -  Any condition that, in the opinion of the study staff, would make participation in the&#xD;
             study unsafe, complicate interpretation of study outcome data, or otherwise interfere&#xD;
             with achieving the study objective.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Justman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Departments of Epidemiology and Medicine, Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayana Moore, PhD</last_name>
    <phone>919-544-7040</phone>
    <phone_ext>11244</phone_ext>
    <email>ayana.moore@fhi360.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Mkumba</last_name>
    <phone>919-544-7040</phone>
    <phone_ext>1234</phone_ext>
    <email>LMkumba@fhi360.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Miami, IDRU at Jackson Memorial Hospital CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UIC Project Wish CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Adolescent Trials Unit CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John's Hopkins CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Prevention</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Prevention Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>37034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University VTEU-CAIMED-PHSU</name>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg</url>
    <description>COVID-19 Nursing Home Data [Internet].2020 [cited 06/08/2020]</description>
  </link>
  <link>
    <url>http://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html</url>
    <description>CDC.Coronavirus Disease 2019 (COVID-19): Groups at Higher Risk for Severe Illness 2020 [updated 05/14/2020]</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

